ClinicalTrials.gg
Active, not recruitingNCT05743621Updated Oct 26, 2026

Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 interventional study of TVB-2640 and Enzalutamide in Prostatic Neoplasms, Castration-Resistant, sponsored by Weill Medical College of Cornell University. Active, not recruiting at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-26.

Sponsored by Weill Medical College of Cornell University · Phase 1, Interventional, and Treatment

How we know

Updated Oct 26, 2026Now Active, not recruitingPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States — 18 open to participants now, 24 under way, 3 of them phase 3. Prostatic Neoplasms, Castration-Resistant · United States.

Enrollment
40th of 43
8 · median 82
Started
2023
with 5 others
Phase 1
15 of 51
5 open now
Primary completion
2026-05
later than 3 of 23 live
Registered
32nd of 51
by date

Among the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, this one is the 40th largest by enrollment of the 43 interventional ones that give a count, is one of 6 that started in 2023, is one of 15 in phase 1, reaches primary completion later than 3 of the 23 other live ones, and was the 32nd registered.

Prostatic Neoplasms, Castration-Resistant

86 studies on the registry are indexed under Prostatic Neoplasms, Castration-Resistant; 29 are open to participants now.

Browse Prostatic Neoplasms, Castration-Resistant studies →

Open to participants now

18 of the 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States are open now. Recruiting first, the newest first:

13 more — sign in →

All 18 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 26 Prostatic Neoplasms, Castration-Resistant studies recruiting now, 22 (85%) set no upper age limit and none (0%) stop at 75 or younger; 1 takes children under 18; none take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 51 studies in Prostatic Neoplasms, Castration-Resistant with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to determine what effects (good and bad) Enzalutamide and TVB-2640 have in the treatment of prostate cancer whose prostate cancer has spread to other parts of their body and that has not gotten better with previous treatment. This study is a Phase I clinical trial. Phase I clinical trials test the side effects of an investigational drug or an investigational combination with another drug. "Investigational" means that the drug is still being studied and research doctors are trying to find out more about it. Although Enzalutamide is already being used to treat men with prostate cancer, combining Enzalutamide with TVB-2640 together in patients with prostate cancer is considered experimental. This research study is being done because additional effective treatments are needed for prostate cancer that has spread and is growing despite hormone suppression. By doing this study, the investigators hope to learn if combining Enzalutamide with TVB-2640 can be done safely. Participation in this research will last about 12 to 24 months after enrollment.

Read the detailed description

This phase I, open-label, dose-escalation study is designed to evaluate the dose limiting toxicities (DLTs) and maximum-tolerated dose (MTD) of TVB-2640 plus Enzalutamide and establish the TVB-2640 dose recommended for further investigation in phase 2 (i.e., recommended phase 2 dose [RP2D]). Patients with a confirmed histological or cytological diagnosis of prostate cancer (PC), evidence of metastatic PC on imaging (bone scan and/or CT/MRI scan), serum testosterone \<50 ng/dl, who had progressed on androgen-depletion therapy (ADT), with documented progressive metastatic castration-resistant prostate cancer (mCRPC) based on Prostate Cancer Working Group 3 (PCWG3) criteria and no previously treatment with cytotoxic chemotherapy are eligible. This study represents the first clinical evaluation of TVB-2640 in combination with Enzalutamide. All patients will receive Enzalutamide monotherapy at the approved dose of 160 mg once daily for 28 days to reach the steady state as determined by measuring Enzalutamide and des-methyl-Enzalutamide levels. Participants who complete the Enzalutamide run-in period will begin oral TVB-2640 at the dose of 100 mg. The dose escalation scheme will be the Bayesian optimal interval (BOIN) design with additional dose levels of 100 mg, 150mg, 200 mg, 250 mg, and 300mg daily. The maximum sample size for the phase I will be 30 patients and the target DLT rate is 25% or less and a maximum of 9 patients at any dose level.

03

Conditions studied

  • Prostatic Neoplasms, Castration-Resistant

Keywords

  • Metastatic Castration-Resistant Prostate Cancer
  • FASN Inhibitor
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years
  • Documented histological or cytological diagnosis of PC
  • Evidence of PC on imaging (bone scan and/or CT/MRI scan)
  • Diagnosis of progressive metastatic, castration resistant prostate cancer
  • Potential participant must be planning to receive Enzalutamide as their of therapy for castration resistant prostate cancer or have previously received up to one line of Abiraterone or an androgen receptor antagonist
  • Willing to undergo a tumor prior to beginning therapy, if recent tissue samples are not available
  • Willing to undergo a tumor biopsy of at least one metastatic site or primary prostate after \~4-6 weeks of therapy with both agents
  • Participants without prior orchiectomy must be currently taking and willing to continue luteinizing hormone-releasing hormone (LHRH) analogue (agonist or antagonist) therapy until permanent discontinuation of study treatment
  • performance status of 0-1
  • Recovery to baseline or ≤ Grade 1 v5 from toxicities related to any prior treatments, unless specified below AE(s) are clinically nonsignificant and/or stable on supportive therapy
  • Adequate organ and marrow function, based upon laboratory criteria within 14 days before first dose of study treatment
  • Sexually active, fertile participants and their partners must agree to use medically accepted methods of (e.g., barrier methods, including male condom with spermicide during the course of the study and for 4 months after the last dose of study treatment
  • Capable of understanding and complying with the protocol requirements and must have signed the document

Exclusion criteria

Exclusion Criteria:

  • Receipt of any type of biologic, or other systemic anticancer therapy (including ) except agents within 4 weeks before first dose of study treatment. Anti-resorptive bone agents are also allowed.
  • Radiation therapy for bone within 2 weeks, any other radiation therapy within 4 weeks before first dose of study treatment. Systemic treatment with radionuclides within 6 weeks before the first dose of study treatment. Participants with ongoing complications from prior radiation therapy are not eligible.
  • Prior exposure to taxane chemotherapy
  • History of pneumonitis
  • Known or cranial epidural disease unless adequately treated with radiotherapy and/or surgery (including radiosurgery) and stable for at least 4 weeks prior to first dose of study treatment after radiotherapy or at least 4 weeks prior to first dose of study treatment after major surgery (e.g., removal or of brain metastasis). Participants must have complete wound healing from major surgery or minor surgery before first dose of study treatment. Eligible participants must be neurologically asymptomatic and without treatment for neurological indications at the time of first dose of study treatment.
  • Participants with clinically significant dry eye or corneal abnormalities
  • Currently taking certain anticoagulation medications, such as coumarin agents (e.g., warfarin), direct thrombin inhibitors (e.g., dabigatran), direct factor Xa inhibitor betrixaban, or inhibitors (e.g., clopidogrel)
  • Participant has (PT)/INR or partial thromboplastin time (PTT) test ≥ 1.3 X the laboratory within 30 days before the first dose of study treatment.
  • Participants should not receive strong CYP2C8 or strong P-gp inhibitors; strong or CYP2C8 inducers; and strong CYP3A4, CYP2C9 and CYP2C19 substrates while participating in the trial, unless utilized with caution to treat a drug-related AE when no alternative is available and discussed with the Medical Monitor.
  • Participant has uncontrolled, significant intercurrent or recent Cardiovascular disorders including, but not limited to, the following conditions:

    i. Congestive heart failure Class 3 or 4, unstable angina pectoris, serious cardiac arrhythmias.

ii. Uncontrolled hypertension defined as sustained blood pressure (BP) >140 mm Hg systolic or >90 mm Hg diastolic despite optimal antihypertensive treatment.

iii. Stroke (including [TIA]), myocardial infarction (MI), or other ischemic event, or thromboembolic event (e.g. deep venous thrombosis, pulmonary embolism) within 6 months before first dose.

  • interval calculated by the Fridericia formula (QTcF) > 470 ms per (ECG) within 28 days before first dose of study treatment.
  • Inability to swallow tablets.
  • Use of herbal products that may decrease PSA levels within 4 weeks prior to enrollment
  • Previously identified allergy or to components of the study treatment formulations.
  • Diagnosis of another type of cancer within 2 years before first dose of study treatment, except for superficial skin cancers, or localized, low-grade tumors deemed cured and not treated with systemic therapy.
  • Any serious and/or unstable pre-existing medical, psychiatric disorder or other conditions that could interfere with participant's safety, obtaining or compliance to the study procedures.
Terms in these criteria, in plain language(20)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    TVB-2640 in combination with Enzalutamide

    Drug: TVB-2640 · Drug: Enzalutamide

Interventions

  • TVB- 2640 at 100 mg, 150mg, 200 mg, 250 mg, or 300mg daily, orally; dose determined by BOIN dose escalation per the protocol

  • 160 mg daily PO

    Also known as: Xtandi

06

What researchers measure

Primary outcomes

  1. Optimal dose of TVB-2640 in combination with Enzalutamide, as determined by the maximum tolerated dose (MTD)

    The maximum tolerated dose (MTD) is defined as the highest dose level at which ≤1 patient experiences a dose-limiting toxicity, as defined in the protocol (DLT). Once all the patients are accrued, the MTD will be determined by performing isotonic regression on the pooled data.

    Time frame: From start of treatment to 28 days after start of TVB-2640 treatment

Secondary outcomes

  1. Number of adverse events (evaluated using the NCI CTCAE v5.0) of different doses of TVB-2640 in combination with Enzalutamide

    All observed AEs will be tabulated and reported as relative frequencies (i.e., fraction of patients with that AE). This will be done by AE and maximum grade experienced within a patient. The fraction of patients with each AE by grade will be estimated with a binomial point estimate and corresponding 95% binomial confidence interval (CI). AEs will be collected until 30 days following the last dose of study drug. AEs will be reported for each different dose of TVB-2640 given.

    Time frame: 12 months

  2. Mean TVB-2640 total exposure (as measured by the area under the drug serum concentration vs. the time from administration curve [AUC])

    Peripheral blood will be drawn at: Day 28: * Pre- enza dose * Post-dose * 1 hours (±5 min) * 2 hours (±5 min) * 4 hours (±30 min) Days 36-37: * Pre-TVB-2640 dose * Post-dose * 2 hours (±5 min) * 4 hours (±30 min) * 6 hours (±30 min) * 8 hours (±30 min) * 24-hours (±1 hour) Days 43-44: * Pre-TVB-2640 dose * Post-dose * 30 minutes (±5 min) * 1 hour (±5 min) * 2 hours (±5 min) * 4 hours (±30 min) * 6 hours (±30 min) * 8 hours (±30 min) * 24-hours (±1 hour) Days 50-51: * Pre-TVB-2640 dose * Post-dose * 30 minutes (±5 min) * 1 hour (±5 min) * 2 hours (±5 min) * 4 hours (±30 min) * 6 hours (±30 min) * 8 hours (±30 min) * 24-hours (±1 hour)

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  3. Mean Enzalutamide total exposure (as measured by the area under the drug serum concentration vs. the time from administration curve [AUC])

    Peripheral blood will be drawn at: Day 28: * Pre- enza dose * Post-dose * 1 hours (±5 min) * 2 hours (±5 min) * 4 hours (±30 min) Days 36-37: * Pre-TVB-2640 dose * Post-dose * 2 hours (±5 min) * 4 hours (±30 min) * 6 hours (±30 min) * 8 hours (±30 min) * 24-hours (±1 hour) Days 43-44: * Pre-TVB-2640 dose * Post-dose * 30 minutes (±5 min) * 1 hour (±5 min) * 2 hours (±5 min) * 4 hours (±30 min) * 6 hours (±30 min) * 8 hours (±30 min) * 24-hours (±1 hour) Days 50-51: * Pre-TVB-2640 dose * Post-dose * 30 minutes (±5 min) * 1 hour (±5 min) * 2 hours (±5 min) * 4 hours (±30 min) * 6 hours (±30 min) * 8 hours (±30 min) * 24-hours (±1 hour)

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  4. Mean maximum serum concentration (Cmax) of TVB-2640

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  5. Mean maximum serum concentration (Cmax) of Enzalutamide

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  6. Mean minimum serum concentration (Cmin) of TVB-2640

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  7. Mean minimum serum concentration (Cmin) of Enzalutamide

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  8. Mean TVB-2640 volume of distribution at steady state

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  9. Mean Enzalutamide volume of distribution at steady state

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  10. Mean time to maximum TVB-2640 serum concentration (Tmax) after administration

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  11. Mean time to maximum Enzalutamide serum concentration (Tmax) after administration

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  12. Mean Serum half-life (T1/2) of TVB-2640

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  13. Mean Serum half-life (T1/2) of Enzalutamide

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  14. Mean TVB-2640 clearance

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  15. Mean Enzalutamide clearance

    Peripheral blood will be drawn at the following times: Day 28: * Pre- enza dose * 1 hours (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose Days 36-37: * Before TVB-2640 administration * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 43-44: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose Days 50-51: * Before TVB-2640 administration * 30 minutes (±5 min) post-dose * 1 hour (±5 min) post-dose * 2 hours (±5 min) post-dose * 4 hours (±30 min) post-dose * 6 hours (±30 min) post-dose * 8 hours (±30 min) post-dose * 24-hours (±1 hour) post-dose

    Time frame: Day 28; Days 36-37; Days 43-44; Days 50-51

  16. Prostate-Specific Antigen (PSA) Response Rate

    The PSA response rate will be evaluated using PCWG3 criteria and defined as the proportion of patients with a PSA decline of at least 50%. Any change from baseline is confirmed by a second measurement at least 3 weeks later. PSA Response Rate will be evaluated using PCWG3 criteria and defined as following: Percentage change from baseline in PSA to 12 weeks post Enzalutamide plus TVB-2640. Only evaluate for patients with at least 12 weeks of treatment, the PSA assessment at 12 weeks (84 days +/-3 days) will be used; Maximum percent decrease in PSA from baseline that occurs at any point after treatment.

    Time frame: Baseline; 12 weeks

  17. Overall radiographic response rate

    Tumor response will be evaluated using the PCWG3 criteria. Patients with measurable disease will be evaluated for clinical benefit as determined by tumor response using RECIST v1.1. Patients with non-measurable bone disease will be evaluated for progression based on the presence of any new lesions by bone scans. Radiographic tumor evaluation will be performed at screening and every 3 cycles or more frequently as determined by the investigator. Using the tumor response that is determined by the investigator, best overall response will be determined using RECIST v1.1. Best overall response is defined as the best response recorded from the start of treatment until disease progression or study exit. The overall response rate will be determined as the number of patients with a confirmed PR or CR divided by the total number of patients evaluable for overall response.

    Time frame: From baseline until disease progression for a maximum of 2 years from enrollment

  18. Overall median progression free survival (PFS)

    Overall progression free survival (PFS) is determined using the PCWG3 criteria. Overall PFS is measured from screening until the time that disease progression (radiographic progressive disease or clinical deterioration) or death is documented, whichever occurs first.

    Time frame: From baseline until disease progression or death from any cause for a maximum of 2 years from enrollment

  19. Median radiographic progression free survival (PFS) as assessed by PCWG3

    Radiographic progression-free survival (rPFS) is determined using the PCWG3 criteria to assess both soft-tissue and bone assessments. The rPFS is measured from screening until the time the first radiographic scan shows disease progression, or until the time of death, whichever occurs first. Patients who do not progress radiographically or did not die prior to study exit are censored on the date of their last dose of Enzalutamide plus TVB-2640. PFS will be summarized with a Kaplan-Meier curve. The Kaplan-Meier estimator will be used to determine the 6-month and 12-month PFS rates. Each estimate will have a corresponding 95% confidence interval. The median PFS will also be estimated with a corresponding 95% confidence interval

    Time frame: From baseline until disease progression for a maximum of 2 years from enrollment

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from Nov 2023 to primary completion in May 2026, 29 months.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 26, 2026: primary completion Jan 2027 → May 2026 and completion Jan 2029 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 30, 2023
First posted
Feb 24, 2023
StartActual
Nov 20, 2023
Primary completionActual
May 12, 2026was Jan 2027
CompletionEst.
Jan 25, 2028was Jan 2029
Last update
Oct 26, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 26, 2026
Primary completion
Jan 25, 2027→May 12, 2026 (actual)
Oct 26, 2026
Study completion
Jan 25, 2029→Jan 25, 2028
Oct 26, 2026
Enrollment
30 (estimated)→8 (actual)
Oct 26, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameOptimal dose of TVB-2640 in combination with Enzalutamide, as determined by the maximum tolerated dose (MTD)Day 28 → From start of treatment to 28 days after start of TVB-2640 treatment
Oct 26, 2026
Show all 1 update
  1. Oct 26, 2026
    Recruiting→Active, not recruiting
    Primary completion Jan 25, 2027→May 12, 2026 (now actual)
    Study completion Jan 25, 2029→Jan 25, 2028
    Enrollment 30 (estimated)→8 (actual)
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameOptimal dose of TVB-2640 in combination with Enzalutamide, as determined by the maximum tolerated dose (MTD)Day 28 → From start of treatment to 28 days after start of TVB-2640 treatment
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05743621
Collaborators
Sagimet Biosciences Inc.
Responsible party
Sponsor
First posted
Feb 24, 2023
Start date
Nov 20, 2023
Primary completion
May 12, 2026
Completion
Jan 25, 2028 (estimated)
Last update
Oct 26, 2026

Study contacts

David Nanus, M.D.
principal investigator · Weill Medical College of Cornell University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: TVB-2640

Start the discussion